

**Kebilidi™ (eladocagene exuparvovec-tneq) Prior Authorization Form**

**Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Member ID#:** \_\_\_\_\_

**Drug Information**

**Physician billing (HCPCS code:** \_\_\_\_\_ **) Start Date:** \_\_\_\_\_

**Billing Provider Information**

**Provider NPI:** \_\_\_\_\_ **Provider Name:** \_\_\_\_\_

**Provider Phone:** \_\_\_\_\_ **Provider Fax:** \_\_\_\_\_

**Prescriber Information**

**Prescriber NPI:** \_\_\_\_\_ **Prescriber Name:** \_\_\_\_\_

**Prescriber Phone:** \_\_\_\_\_ **Prescriber Fax:** \_\_\_\_\_ **Specialty:** \_\_\_\_\_

**Criteria**

**For Authorization: (Only one Kebilidi™ treatment will be approved per member per lifetime):**

1. Please indicate member's diagnosis:
  - Aromatic L-amino acid decarboxylase (AADC) deficiency
  - Other: \_\_\_\_\_
2. Was diagnosis confirmed by the following:
  - a. Genetic testing confirming biallelic pathogenic or likely pathogenic mutations in the *DDC* gene (*results of genetic testing must be submitted*) Yes \_\_\_ No \_\_\_
  - b. Functional confirmation with measured diagnostic variations in AADC enzyme activity in plasma and/or levels of neurotransmitter metabolites in cerebrospinal fluid (CSF) (*results of testing must be submitted*) Yes \_\_\_ No \_\_\_
3. For females of reproductive potential:
  - a. Is the member pregnant? Yes \_\_\_ No \_\_\_
  - b. Will the member have a negative pregnancy test prior to Kebilidi™ administration? Yes \_\_\_ No \_\_\_
4. Is Kebilidi™ prescribed by a neurologist, neurosurgeon, or a specialist with expertise in the treatment of AADC deficiency? Yes \_\_\_ No \_\_\_
5. Does the member have confirmed skull maturity as assessed by neuroimaging? Yes \_\_\_ No \_\_\_
6. Will Kebilidi™ be administered by intraputaminial infusion in a medical center that specializes in stereotactic neurosurgery in addition to the preparation and infusion of Kebilidi™? Yes \_\_\_ No \_\_\_
7. Will Kebilidi™ be shipped via cold chain supply to the facility where the member is scheduled to receive treatment? Yes \_\_\_ No \_\_\_ Name of facility: \_\_\_\_\_
  - a. Is the facility capable of adhering to the storage, handling, and preparation requirements as described in the package labeling? Yes \_\_\_ No \_\_\_
8. Will Kebilidi™ be administered using an FDA-authorized cannula for intraparenchymal infusion (e.g., ClearPoint® SmartFlow® Neuro Cannula)? Yes \_\_\_ No \_\_\_

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Failure to complete this form in full and attach requested clinical notes will result in processing delays.**

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy  
Pharmacy Management Consultants  
Product Based Prior Authorization Unit  
Fax: 1-800-224-4014  
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*